Aug 28, 2025
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
Jun 17, 2025
Foresee Pharmaceuticals announces reaching a significant milestone, of complete enrollment of its Phase 3 Casppian trial for patients with Central Precocious Puberty (CPP)
May 15, 2025
Foresee Pharmaceuticals Announces First Patient Dosed in the Phase 2 WINDWARD Study of the ALDH2 Activator Mirivadelgat for Patients with Pulmonary Hypertension-Associated Interstitial Lung Disease (PH-ILD)
May 14, 2025
Foresee Pharmaceuticals Announces a Keynote Oral Presentation and Participation at the 2025 American Thoracic Society International Conference
Feb 17, 2025
Foresee Pharmaceuticals Receives the Third Positive Recommendation from the DSMB to Continue the Casppian Study
Feb 10, 2025
Foresee Pharmaceuticals Announces Acceptance of An Abstract for Presentation at ASCO Genitourinary Cancers Symposium 2025
Jan 13, 2025
Foresee Pharmaceuticals Announces the PDUFA Goal Date for the 3-month Version of CAMCEVI is August 29, 2025
Dec 04, 2024
Foresee Pharmaceuticals Announces Completion of US$42.1 Million Financing
Nov 15, 2024
Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty
Oct 29, 2024
Foresee Pharmaceuticals Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer
Oct 20, 2024
Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor.
Aug 09, 2024
Foresee Pharmaceuticals Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectable Products
Apr 30, 2024
Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020
Apr 29, 2024
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference
Apr 01, 2024
Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty
Dec 24, 2020
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
Nov 17, 2020
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China
Oct 08, 2020
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA
Jul 27, 2020
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg
Mar 29, 2019
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg